MiroBio

Autoimmune diseases occur when the immune system attacks the body’s own tissues – and most current treatments suppress the whole immune system.

MiroBio is developing therapies that activate the body’s natural immune ‘brakes’, restoring balance without broad immunosuppression. The company was co-founded by Tim Funnell, an OSE Entrepreneur-in-Residence, and built on 15 years of Oxford research into immune signalling by co-founders Professors Richard Cornall and Simon Davis.

It was acquired by Gilead Sciences for approximately $405m in 2022.